Last updated: February 17, 2026
What Is NDC 50111-0915?
NDC 50111-0915 corresponds to Bavencio (avelumab) injectable, a PD-L1 inhibitor approved for multiple cancer types, including metastatic Merkel cell carcinoma, bladder cancer, and other indications per FDA approvals. As a monoclonal antibody, it functions by blocking PD-L1 to stimulate immune response.
Current Market Position
Bavencio entered the market post-approval in 2017, developed by Pfizer and Merck KGaA. It is marketed primarily in the U.S., with international distribution and approval in several countries. The drug competes with other immune checkpoint inhibitors like Keytruda (pembrolizumab) and Tecentriq (atezolizumab).
Key sales data:
- 2021 U.S. sales crossed $400 million.
- Global sales in 2022 approximated $650 million.
- Growth driven by approvals for additional indications, including Merkel cell carcinoma, bladder cancer, and combination regimens.
Market Size and Demand Drivers
Indications and Patient Population
| Indication |
Estimated Patient Pool* |
| Merkel cell carcinoma (MCC) |
1,500-2,000 patients/year in US |
| Urothelial carcinoma (UC) |
82,000 new cases/year in US |
| Other indications (melanoma, etc.) |
10,000+ (combined) |
*Data sources: American Cancer Society and FDA label indications.
Key Factors Influencing Demand
- Expanded FDA approvals increase eligible patient populations.
- Adoption driven by superior efficacy or tolerability compared to prior therapies.
- Payer coverage and formulary access affect prescription volume.
- Competitive landscape with other PD-L1/PD-1 inhibitors.
Market Opportunities and Challenges
Opportunities
- Growing adoption in combination regimens, e.g., with tyrosine kinase inhibitors or chemotherapy.
- Potential for label expansion into earlier treatment lines or other cancers.
- Increasing global access, especially in Europe and Asia.
Challenges
- Patient access remains constrained by high costs and reimbursement issues.
- Competition with established PD-1/PD-L1 agents.
- Biosimilar development may threaten future pricing power.
Pricing Analysis and Projections
Current Pricing
- U.S. List Price: Approximately $10,000 to $13,000 per 200 mg vial.
- Treatment Course Cost: Around $150,000 per year for typical regimens.
- Discounting and insurance negotiations reduce actual transaction prices.
Pricing Trends
- Prices for biologics like Bavencio generally increase by 3-5% annually, driven by inflation and R&D costs.
- Payer pressure and biosimilar threats may restrain future pricing increases.
Projection Models
| Year |
Estimated U.S. Sales ($ Millions) |
Assumptions |
| 2023 |
700 |
Market stability, continued indications expansion |
| 2024 |
850 |
Adoption growth, slight price increase |
| 2025 |
1,050 |
Additional indications, increased global sales |
Global sales may reach $1.2 billion by 2025, assuming steady growth and market penetration.
Factors Affecting Future Pricing
- Regulatory Outcomes: Expanded labels or new formulations could allow premium pricing.
- Market Competition: Entry of biosimilars or generics could reduce prices.
- Reimbursement Policies: CMS and private payers may impose stricter controls.
- Manufacturing Costs: Stable, but potential reduction with process improvements.
Summary
The drug's market is moderately mature with growth driven by expanding indications. Price projections indicate a steady increase influenced by volume growth and inflation, tempered by competitive and reimbursement pressures. The potential for regulatory expansion offers opportunities for higher pricing, while biosimilar entry poses a risk to margins.
Key Takeaways
- Bavencio’s global sales could reach approximately $1.2 billion by 2025.
- U.S. per treatment cost remains around $150,000, with projected slight increases.
- Demand driven by expansion of approved indications, including bladder and Merkel cell carcinoma.
- Competition from Keytruda and Tecentriq is significant.
- Biosimilar and advanced therapies could pressure prices over the medium term.
FAQs
Q1: What is the primary indication for NDC 50111-0915?
A: Treatment of metastatic Merkel cell carcinoma and urothelial carcinoma.
Q2: How does Bavencio compare price-wise to competitors?
A: Similar biologics like Keytruda and Tecentriq have variable pricing, with Bavencio’s list price around $10,000–$13,000 per 200 mg vial.
Q3: What factors could impact Bavencio's future market share?
A: Biosimilar competition, FDA label expansion, and emerging therapies could reduce market share.
Q4: Are there upcoming patent protections that influence pricing?
A: Patent expiration dates are not publicly specified but generally extend into the late 2020s for key formulations, allowing temporary pricing insulation.
Q5: What strategies could extend Bavencio’s market viability?
A: Expanding indications, optimizing combination regimens, and international market penetration.
References
[1] U.S. Food and Drug Administration (FDA). Bavencio (avelumab) prescribing information.
[2] IQVIA, 2022 sales data.
[3] American Cancer Society. Cancer statistics.
[4] Evaluate Pharma. Biopharma Market Data, 2023.
